180 related articles for article (PubMed ID: 34738874)
21. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
Zhang S; Chen Z; Shi P; Fan S; He Y; Wang Q; Li Y; Ramalingam SS; Owonikoko TK; Sun SY
Theranostics; 2021; 11(8):3964-3980. PubMed ID: 33664875
[TBL] [Abstract][Full Text] [Related]
22. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim DW; Ahn MJ; Yang JC; Zhang X
Sci Transl Med; 2016 Dec; 8(368):368ra172. PubMed ID: 27928026
[TBL] [Abstract][Full Text] [Related]
23. Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells.
Nakagawa N; Miyake N; Ochi N; Yamane H; Takeyama M; Nagasaki Y; Ikeda T; Yokota E; Fukazawa T; Nakanishi H; Harada D; Kiura K; Takigawa N
Exp Cell Res; 2021 Dec; 409(2):112940. PubMed ID: 34808132
[TBL] [Abstract][Full Text] [Related]
24. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
26. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
[TBL] [Abstract][Full Text] [Related]
27. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
28. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
29. The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Remon J; Menis J; Hasan B; Peric A; De Maio E; Novello S; Reck M; Berghmans T; Wasag B; Besse B; Dziadziuszko R
Clin Lung Cancer; 2017 Sep; 18(5):583-588. PubMed ID: 28341106
[TBL] [Abstract][Full Text] [Related]
30. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
32. MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.
Gu J; Yao W; Shi P; Zhang G; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Aug; 126(16):3788-3799. PubMed ID: 32497272
[TBL] [Abstract][Full Text] [Related]
33. FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M; Xu J; Liu Y; Li Y; He T; Ding L; He Y; Yi Y; Li F; Guo R; Gao Y; Li R; Li L; Fu M; Hu Q; Luo Y; Zhang C; Qin K; Yi J; Yu S; Yang J; Chen H; Wang L; Li Z; Dong B; Qi S; Ouyang L; Zhang Y; Cao Y; Xiao ZJ
Nat Commun; 2021 Oct; 12(1):5919. PubMed ID: 34635651
[TBL] [Abstract][Full Text] [Related]
34. Targeting
Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
[No Abstract] [Full Text] [Related]
35. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.
Xiong X; Fu L; Wang L; Cai H; Li L; Jiang H; Duan W; Mei C
Invest New Drugs; 2009 Feb; 27(1):1-11. PubMed ID: 18493719
[TBL] [Abstract][Full Text] [Related]
36. Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Qian G; Guo J; Vallega KA; Hu C; Chen Z; Deng Y; Wang Q; Fan S; Ramalingam SS; Owonikoko TK; Wei W; Sun SY
Mol Cancer Res; 2021 Oct; 19(10):1622-1634. PubMed ID: 34183449
[TBL] [Abstract][Full Text] [Related]
37. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
[TBL] [Abstract][Full Text] [Related]
38. Characterization of
Emdal KB; Dittmann A; Reddy RJ; Lescarbeau RS; Moores SL; Laquerre S; White FM
Mol Cancer Ther; 2017 Nov; 16(11):2572-2585. PubMed ID: 28830985
[TBL] [Abstract][Full Text] [Related]
39. Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line.
Verusingam ND; Chen YC; Lin HF; Liu CY; Lee MC; Lu KH; Cheong SK; Han-Kiat Ong A; Chiou SH; Wang ML
J Chin Med Assoc; 2021 Mar; 84(3):248-254. PubMed ID: 33009209
[TBL] [Abstract][Full Text] [Related]
40. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
